1. Academic Validation
  2. Discovery of Phthalazinone Derivatives as Novel Hepatitis B Virus Capsid Inhibitors

Discovery of Phthalazinone Derivatives as Novel Hepatitis B Virus Capsid Inhibitors

  • J Med Chem. 2020 Aug 13;63(15):8134-8145. doi: 10.1021/acs.jmedchem.0c00346.
Wuhong Chen 1 Feifei Liu 2 3 Qiliang Zhao 1 3 Xinna Ma 2 4 Dong Lu 1 Heng Li 2 3 Yanping Zeng 1 3 Xiankun Tong 2 Limin Zeng 1 Jia Liu 1 Li Yang 2 Jianping Zuo 2 4 Youhong Hu 1 3 5
Affiliations

Affiliations

  • 1 State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 ZuChongZhi Road, Shanghai 201203, China.
  • 2 Laboratory of Immunopharmacology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 ZuChongZhi Road, Shanghai 201203, China.
  • 3 University of Chinese Academy of Sciences, No. 19A Yuquan Road, Beijing 100049, China.
  • 4 Laboratory of Immunology and Virology, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China.
  • 5 School of Pharmaceutical Science and Technology, Hangzhou Institute for Advanced Study, Hangzhou 310024, China.
Abstract

HBV capsid assembly has been viewed as an attractive target for new Antiviral therapies against HBV. On the basis of a lead compound 4r, we further investigated this target to identify novel active compounds with appropriate anti-HBV potencies and improved pharmacokinetic (PK) properties. Structure-activity relationship studies based on metabolic pathways of 4r led to the identification of a phthalazinone derivative 19f with appropriate anti-HBV potencies (IC50 = 0.014 ± 0.004 μM in vitro), which demonstrated high oral bioavailability and liver exposure. In the AAV-HBV/mouse model, administration of 19f resulted in a 2.67 log reduction of the HBV DNA viral load during a 4-week treatment with 150 mg/kg dosing twice daily.

Figures
Products